Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.34 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029857 | 0.80 | ADORA2A (0.43) | ADORA2AADORA1AXLPRKCIDYRK1A | |
| SCHEMBL7655789 | 0.79 | DYRK1A (0.42) | ADORA2AADORA1DYRK1AKDM4EL3MBTL1 | |
| SCHEMBL10012874 | 0.79 | ADORA2A (0.39) | ADORA2AADORA1AXLPRKCIDYRK1A | |
| SCHEMBL161735 | 0.79 | ADORA2A (0.39) | ADORA2AADORA1AXLPRKCIDYRK1A | |
| SCHEMBL20067823 | 0.77 | KDM4E (0.46) | ADORA2AADORA1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL4016987 | 0.76 | MAPT (0.39) | ADORA2AADORA1DYRK1AKDM4ECYP1A2 | |
| SCHEMBL14004647 | 0.76 | ADORA2A (0.37) | ADORA2AADORA1AXLPRKCIDYRK1A | |
| SCHEMBL30657785 | 0.76 | METAP2 (0.40) | ADORA2AADORA1AXLPRKCIKMT2A | |
| SCHEMBL3124523 | 0.76 | PRKCI (0.46) | ADORA2AADORA1AXLPRKCIDYRK1A | |
| SCHEMBL15557725 | 0.75 | PRKCI (0.39) | ADORA2AADORA1AXLPRKCIDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | Université de Liège (BE) | 2025-06-03 | — | — | US | disclosed |
| CN-113329753-B | Pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, pollution and fouling | 列日大学 | 2024-08-13 | — | — | CN | disclosed |
| EP-3955929-B1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | UNIV LIEGE (BE) | 2024-05-15 | — | — | EP | disclosed |
| CN-111386271-B | Pyrimidine derivatives for the prevention and treatment of bacterial infections | 列日大学 | 2023-05-30 | — | — | CN | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| US-11434241-B2 | Pyrimidine derivatives for prevention and treatment of bacterial infections | Université de Liège (BE) | 2022-09-06 | — | — | US | disclosed |
| CN-109328187-B | Novel compound with FGFR (FGFR) inhibitory activity as well as preparation and application thereof | 中国科学院上海药物研究所 | 2022-04-26 | — | — | CN | disclosed |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2021-09-23 | — | — | US | disclosed |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2021-09-23 | — | — | US | disclosed |
| US-5646128-A | TREATING INFLAMMATION, SEPSIS, SEPTIC SHOCK, BURNS | GENSIA, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0496617-A1 | Adenosine kinase inhibitors | GENSIA, INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| EP-0085440-B1 | PRODUCTION OF 4-CHLORO-7-(2,3,5-TRI-O-BENZYL-BETA-D-ARABINOFURANOSYL)-7H-PYRROLO(2,3-D) PYRIMIDINE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1985-10-09 | — | — | EP | disclosed |
| EP-0057548-B1 | 7-BETA-D-ARABINOFURANOSYL-7H-PYRROLO(2,3-D)PYRIMIDINE-4-AMINE 5'-PHOSPHATE COMPOUNDS USEFUL AS ANTIVIRAL AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS, AND PROCESSES FOR PRODUCING THE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4439604-A | 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production | WARNER-LAMBERT COMPANY (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0085440-A1 | Production of 4-chloro-7-(2,3,5-tri-O-benzyl-beta-D-arabinofuranosyl)-7H-pyrrolo(2,3-d) pyrimidine compounds | WARNER-LAMBERT COMPANY (US) | 1983-08-10 | — | — | EP | disclosed |
| US-4352795-A | 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production | WARNER-LAMBERT COMPANY (US) | 1982-10-05 | — | — | US | disclosed |
| EP-0057548-A2 | 7-Beta-D-arabinofuranosyl-7H-pyrrolo(2,3-d)pyrimidine-4-amine 5'-phosphate compounds useful as antiviral agents, pharmaceutical compositions containing the compounds, and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1982-08-11 | — | — | EP | disclosed |
| US-3988338-A | PLANT GROWTH REGULATORS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | PIGS, TYMP, TYMS | ADORA2A 288/4885ADORA1 379/4885AXL 206/4885 |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | PIGS, TYMP, TYMS | ADORA2A 288/4885ADORA1 379/4885AXL 206/4885 |
| US-11434241-B2 | Pyrimidine derivatives for prevention and treatment of bacterial infections | TYMP, TYMS, UMPS | ADORA2A 147/4885ADORA1 120/4885AXL 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.